Literature DB >> 8289491

P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?

J V Melo1, H Myint, D A Galton, J M Goldman.   

Abstract

Two-thirds of patients with Philadelphia (Ph) chromosome-positive acute lymphoblastic leukaemia (ALL) have a breakpoint in the minor breakpoint cluster region (m-bcr) of the BCR gene, which results in an e1a2 transcript and a P190BCR-ABL fusion protein. This type of genomic rearrangement occurs very rarely in chronic myeloid leukaemia (CML); it has been reported in only four cases. We describe here a fifth case of P190 CML in which the cytomorphological characteristics were intermediate between CML and chronic myelomonocytic leukaemia (CMML). This case, and the four reported previously, had a consistent and significant monocytosis with a low neutrophil/monocyte ratio in the peripheral blood, resembling CMML. On the other hand, they also had a high percentage of circulating immature granulocytes, basophilia and low neutrophil alkaline phosphatase (NAP) score, which are more commonly found in classical CML. Thus, P190 CML may be a specific form of CML, in which the myeloproliferative process includes the monocytic, as well as the granulocytic lineage. Since the molecular defect in CML is thought to involve a pluripotent stem cell, the different effects of P210BCR-ABL and P190BCR-ABL in CML must reflect the somewhat wider spectrum of activity of the P190BCR-ABL. Other patients with atypical CML or CMML who lack a Ph chromosome may also have an m-bcr breakpoint which would not be detected on standard Southern blots, but which would be detectable by polymerase chain reaction amplification of reverse transcribed RNA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8289491

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  19 in total

1.  Molecular basis of myelodysplastic/myeloproliferative neoplasms.

Authors:  Andreas Reiter; Rosangela Invernizzi; Nicholas C P Cross; Mario Cazzola
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

Review 2.  Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.

Authors:  Philip A Thompson; Hagop M Kantarjian; Jorge E Cortes
Journal:  Mayo Clin Proc       Date:  2015-10       Impact factor: 7.616

3.  Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Authors:  Craig R Soderquist; Mark D Ewalt; David R Czuchlewski; Julia T Geyer; Heesun J Rogers; Eric D Hsi; Sa A Wang; Carlos E Bueso-Ramos; Attilio Orazi; Daniel A Arber; Elizabeth O Hexner; Daria V Babushok; Adam Bagg
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

4.  A variant form of myelodysplastic syndrome with Ph- minor-BCR/ABL transcript.

Authors:  T Wakayama; Y Maniwa; H Ago; N Kakazu; T Abe
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

5.  Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.

Authors:  Dushyant Verma; Hagop M Kantarjian; Dan Jones; Rajyalakshmi Luthra; Gautam Borthakur; Srdan Verstovsek; Mary Beth Rios; Jorge Cortes
Journal:  Blood       Date:  2009-06-16       Impact factor: 22.113

6.  A common phosphotyrosine signature for the Bcr-Abl kinase.

Authors:  Valerie L Goss; Kimberly A Lee; Albrecht Moritz; Julie Nardone; Erik J Spek; Joan MacNeill; John Rush; Michael J Comb; Roberto D Polakiewicz
Journal:  Blood       Date:  2006-02-23       Impact factor: 22.113

Review 7.  Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.

Authors:  Christian Sillaber; Matthias Mayerhofer; Hermine Agis; Verena Sagaster; Christine Mannhalter; Wolfgang R Sperr; Klaus Geissler; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

8.  Chronic myeloid leukemia presenting ALL-type BCR/ABL transcript.

Authors:  Y Kunieda; M Okabe; M Kurosawa; T Itaya; M Kakinuma; T Miyazaki
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

9.  Extramedullary blast crisis as initial presentation in chronic myeloid leukemia with the e1a2 BCR-ABL1 transcript: A case report.

Authors:  D I Ai; Wei Liu; Gary Lu; Keyur Pravinchandra Patel; Z I Chen
Journal:  Mol Clin Oncol       Date:  2015-09-09

10.  Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.

Authors:  Ellen Weisberg; Lolita Banerji; Renee D Wright; Rosemary Barrett; Arghya Ray; Daisy Moreno; Laurence Catley; Jingrui Jiang; Elizabeth Hall-Meyers; Maira Sauveur-Michel; Richard Stone; Ilene Galinsky; Edward Fox; Andrew L Kung; James D Griffin
Journal:  Blood       Date:  2008-01-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.